Steven Wijnen, The Netherlands Cancer Institute, Amsterdam, Netherlands, discusses the impact of Fc-gamma receptor affinity on patient outcomes in relation to immunotherapy in melanoma, noting that the effect depends on the specific antibody administered, such as anti-PD-1 or anti-CTLA-4, and the cell type it binds to. While certain Fc-engineered antibodies against anti-CTLA-4 may improve patient outcomes, caution is advised when administering anti-PD-1 to patients with specific SNPs due to potential depletion of CD8 cells in the tumor. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.